Partner with Trevi Therapeutics

We are actively seeking ex-US commercial partners who share our dedication to helping improve the quality of life for patients with chronic cough.

Haduvio Overview:

  • 18 issued US and foreign patents with terms expiring from 2026 to 2032 and additional applications with terms, if issued, expiring from 2032 to 2041.
  • Only oral dual acting MOA in clinical development that works both peripherally and centrally to rebalance the kappa and mu receptors. 

for partnering inquiries